Irnocam 40 Injection contains Irinotecan at a concentration of 20 mg/ml and is indicated for the treatment of various malignancies, including metastatic colorectal cancer. Irinotecan is a topoisomerase I inhibitor that interferes with DNA replication and transcription, leading to apoptosis of rapidly dividing cancer cells. This chemotherapeutic agent is administered intravenously, typically as part of combination regimens, to enhance antitumor efficacy. The dosing of Irnocam 40 Injection should be carefully individualized based on patient tolerance, hepatic function, and hematologic status to minimize adverse effects. Common side effects include neutropenia, diarrhea, nausea, vomiting, and alopecia, with early-onset cholinergic symptoms such as abdominal cramping and increased salivation also reported. Close monitoring of blood counts and liver function tests is essential during therapy. Irnocam 40 Injection is contraindicated in patients with known hypersensitivity to Irinotecan or its components and should be used with caution in individuals with pre-existing gastrointestinal disorders or compromised bone marrow function. Adequate hydration and supportive care are recommended to manage side effects. This product should be administered under the supervision of an experienced oncologist in a healthcare setting equipped for chemotherapy administration and emergency management.